Breaking News, Collaborations & Alliances

Cartherics, Catalent Expand Partnership

Catheric to use Catalent’s iPSC line for the manufacture and commercialization of iPSC-derived Chimeric Antigen Receptor Natural Killer (CAR-NK) cell therapies.

Author Image

By: Charlie Sternberg

Associate Editor

Cartherics Pty Ltd, a biotechnology company developing off‑the‑shelf immune cell therapies for high‑impact women’s diseases, and Catalent Inc. have signed an amended commercial license agreement enabling the use of a Catalent cGMP‑compliant induced pluripotent stem cells (iPSC) line for the manufacture and commercialization of Cartherics’ iPSC-derived Chimeric Antigen Receptor Natural Killer (CAR-NK) cell therapies. The agreement supports Cartherics’ mission to develop immune cell therapy produc...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters